Volex (AIM: VLX) upgrades FY2026 revenue to at least $1.22bn as AI data centre demand doubles and board eyes Main Market move
Can inhaled nintedanib improve tolerability and adherence in IPF treatment, according to Avalyn Pharma Inc.?
Read More 2 minute read Pharma Industry News Alkermes expands Phase 1 trial of ALKS 4230 in combination with KEYTRUDA for advanced solid tumors Irish biopharmaceutical company Alkermes has announced an expansion of its ongoing Phase 1 trial to evaluate the safety… bypharmanewsdailySeptember 11, 2018
